Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645703 | 0.87 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL27605658 | 0.86 | KMT2A (0.52) | KMT2AEPHX2MDM4TP53 | |
| SCHEMBL30492079 | 0.84 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL27724932 | 0.84 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL27724933 | 0.84 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL1808220 | 0.84 | KMT2A (0.53) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL17541295 | 0.83 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30749159 | 0.83 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30139101 | 0.83 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL1746631 | 0.83 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233246-B2 | Antibody and antibody fragment introduced new modification sites | KYOWA HAKKO KIRIN CO., LTD (JP) | 2019-03-19 | — | — | US | disclosed |
| EP-2554669-B1 | NOVEL ANTIBODY HAVING MODIFICATION SITE INTRODUCED THEREIN, AND ANTIBODY FRAGMENT | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-09-19 | — | — | EP | disclosed |
| US-20160039937-A1 | NOVEL ANTIBODY AND ANTIBODY FRAGMENT INTRODUCED NEW MODIFICATION SITES | KYOWA HAKKO KIRIN CO., LTD (JP) | 2016-02-11 | — | — | US | disclosed |
| US-9150639-B2 | Antibody and antibody fragment introduced new modification sites | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2554669-A1 | NOVEL ANTIBODY HAVING MODIFICATION SITE INTRODUCED THEREIN, AND ANTIBODY FRAGMENT | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-20120009621-A1 | NOVEL ANTIBODY AND ANTIBODY FRAGMENT INTRODUCED NEW MODIFICATION SITES | KYOWA HAKKO KIRIN CO., LTD (JP) | 2012-01-12 | — | — | US | disclosed |